Form 4: Climb Bio SVP, Finance and CAO, Emily Pimblett, Reports Stock Option Grant
SEC Form 4 Filing
Emily Pimblett, SVP, Finance and CAO of Climb Bio, Inc., reports the grant of stock options for 100,000 shares of common stock.
Summary
- On January 13, 2025, Emily Pimblett, SVP, Finance and CAO of Climb Bio, Inc., was granted stock options to purchase 100,000 shares of common stock at an exercise price of $1.92 per share.
- The options vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder vest in 36 equal monthly installments through January 13, 2029, contingent upon continued service.
- The options expire on January 12, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive.
Positives
- The grant of stock options aligns the interests of the SVP, Finance and CAO with the long-term success of Climb Bio, Inc.
- The vesting schedule incentivizes continued service and contribution to the company.
Future Outlook
The vesting schedule of the stock options suggests an expectation of continued service and contribution from the Reporting Person over the next four years.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
- The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance and retention.
- Comparable companies in the biotech sector, such as Amgen, Gilead Sciences, and Biogen, also utilize stock options as part of their executive compensation plans.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for management to drive long-term value.
- Employees may see the grant as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 01/13/2025 | Date of earliest transaction (stock option grant date) |
| 01/13/2025 | Grant Date of the stock options |
| 01/13/2026 | First vesting date for 25% of the shares |
| 01/13/2029 | Final vesting date for the remaining shares |
| 01/12/2035 | Expiration date of the stock options |
| 01/15/2025 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.